EQUITY RESEARCH - COMPANY REPORT

BANGKOK DUSIT MEDICAL SERVICES

THAILAND / HEALTH CARE SERVICES

Potential record high earnings in 1Q24

- Expect 1Q24 core profit to hit a new record high and grow 16% y-y to THB4.0b, driven by both Thai and international patient revenue;
- Strong earnings growth momentum anticipated in 2Q24 due to a smaller impact from Ramadan;
- Maintain BUY with DCF-based TP of TH35.0/shr.

Expect 1Q24 revenue to hit a record high and grow by 11% y-y

We expect 1Q24 revenue to grow by 11% y-y. Thai patient revenue should grow by 10% y-y as the number of influenza, RSV and Covid cases have remained high since 4Q23. International patient revenue should grow by 12-14% y-y in the quarter, driven by Chinese patients, especially expat and European patients following the high tourism season. However, Middle East patient revenue should be relatively flat y-y. Growth from the UAE, Qatar and Saudi Arabia should be offset by a decline in Kuwaiti patients (estimated to drop by double digits y-y), since the Kuwait government has recalibrated and cut the payment guarantee for its citizens to seek treatments overseas. We estimate the 1Q24 EBITDA margin to improve to 25.0% (vs 24.6% in 1Q23) due to strong revenue growth. As a result, we forecast 1Q24 core profit to grow by 16% y-y and hit a record high at THB4.0b.

Paolo Phaholyothin rebranded to Phyathai Phaholyothin

BDMS recently rebranded Paolo Phaholyothin to Phyathai Phaholyothin to improve the overall service and align with the lifestyle of the population in the area. Paolo Phaholyothin (220 beds) recorded revenue of cTHB2.5b in 2023 (2-3% of total revenue). We believe there is the potential for the hospital to improve its revenue and EBITDA margin profile to match Phyathai 2 (262 beds), which is located only 3 km distant, and generate revenue of cTHB5b in 2023.

Expect 2024 core profit to grow by 14% to THB16.4b

We expect the strong earnings growth momentum to continue in 2Q24 due to the low base and a smaller impact from Ramadan in 2Q24 compared to 2Q23 (Ramadan was from 10 Mar to 9 Apr in 2024 vs 22 Mar to 21 Apr in 2023). We forecast 2024 revenue to grow by 10% (vs management's target of 10-12%) and the EBITDA margin to improve to 24.7% (vs management's target of 24-25% and 24.2% in 2023). This would lead 2024 core profit to grow by 14% to THB16.4b.

Trades at an attractive valuation

We maintain our forecast and our 2024 DCF-TP of THB35.0/shr. BDMS is trading at an attractive valuation of 28x 2024E P/E, lower than its five-year average of 31x.



Teerapol Udomvej, CFA

Fundamental Investment Analyst on Securities; License no. 080523 teerapol.udo@fssia.com, +66 2646 9969



FSSIA ESG rating

BDMS TB


BUX

UNCHANGED

TARGET PRICE	THB35.00
CLOSE	THB28.50
UP/DOWNSIDE	+22.8%
PRIOR TP	THB35.00
CHANGE IN TP	UNCHANGED
TP vs CONSENSUS	+0.2%

KEY STOCK DATA

YE Dec (THB m)	2023	2024E	2025E	2026E
Revenue	102,110	112,311	121,304	131,022
Net profit	14,375	16,413	17,928	19,652
EPS (THB)	0.90	1.03	1.13	1.24
vs Consensus (%)	-	5.4	6.3	5.5
EBITDA	24,740	27,717	30,179	32,859
Recurring net profit	14,375	16,413	17,928	19,652
Core EPS (THB)	0.90	1.03	1.13	1.24
Chg. In EPS est. (%)	-	-	-	-
EPS growth (%)	14.0	14.2	9.2	9.6
Core P/E (x)	31.5	27.6	25.3	23.0
Dividend yield (%)	2.3	2.5	2.5	2.8
EV/EBITDA (x)	18.8	16.7	15.2	13.8
Price/book (x)	4.8	4.5	4.2	4.0
Net debt/Equity (%)	8.8	6.2	1.1	(3.9)
ROE (%)	15.5	16.8	17.3	17.8



Sources: Bloomberg consensus; FSSIA estimates

PREPARED BY FSS INTERNATIONAL INVESTMENT ADVISORY SECURITIES CO LTD (FSSIA). ANALYST CERTIFICATION AND IMPORTANT DISCLOSURES CAN BE FOUND AT THE END OF THIS REPORT

Investment thesis

BDMS has aggressively expanded its hospital network from 10 in 2004 to 59 currently. The company had a high capex level averaging 17% of revenue over 2013-19. It is now at the tail end of its capex cycle, as it has already achieved its target of 50 hospitals.

BDMS plans to focus on organic growth. We expect its EBITDA margin to be maintained at a high level of 24-25% over 2023-25 (vs 22% in 2019), led by a higher utilization rate, its Centre of Excellence (CoE) project, and the turnaround of loss-making hospitals.

BDMS has a healthy balance sheet with 2023 net D/E at only 0.1x. FCFF should accelerate, based on our estimates, and this would provide an upside to its dividend payouts.

Company profile

BDMS is the largest healthcare provider in terms of market capital in Thailand. It operates 59 hospitals under six brands.

www.bangkokhospital.com


Principal activities (revenue, 2023)

- Thai patient revenue 69.4 %
- International patient revenue 25.7
- Other revenue 4.9 %

Source: Bangkok Dusit Medical Services

Major shareholders

- Prasert Prasarttong-Osoth 12.5
- Thai NVDR 12.4 %
- Poramaporn Prasarttong-Osoth -5.2 %
- Others 69.9 %



Source: Bangkok Dusit Medical Services

Catalysts

Key potential growth drivers include 1) higher insurance patient revenue; 2) rising demand from medical tourists; and 3) an improving EBITDA margin led by CoE hospitals.

Risks to our call

Downside risks to our DCF-based target price include 1) a slowdown in international patients due to economic concerns, political protests or floods; 2) regulatory risks from drug prices and medical bill controls; and 3) higher-than-expected capex and opex for CoE projects.

Event calendar

 Date
 Event

 May 2024
 1Q24 results announcement

Key assumptions

	2024E	2025E	2026E
	(%)	(%)	(%)
No. of hospitals (no.)	61	63	66
OPD volume growth	5	4	4
OPD revenue / patient growth	5	4	4
IPD volume growth	5	4	4
IPD revenue / patient growth	5	4	4

Source: FSSIA estimates


Earnings sensitivity

- For every 1% increase in patient volume, we project 2024 earnings to rise by 2%, and vice versa, all else being equal.
- For every 1% increase in EBITDA margin, we project 2024 earnings to rise by 6%, and vice versa, all else being equal.

Source: FSSIA estimates




Exhibit 1: Thai patient revenue, quarterly




Sources: BDMS; FSSIA estimates

Exhibit 3: Utilization rate




Source: BDMS; FSSIA estimates

Exhibit 5: Thai patient revenue forecast




Note: Includes Covid-related revenue of THB10.1b in 2021 and THB9.0b in 2022 Sources: BDMS; FSSIA estimates

Exhibit 2: International patient revenue, quarterly




Sources: BDMS; FSSIA estimates

Exhibit 4: EBITDA margin trend, quarterly



Sources: BDMS; FSSIA estimates

Exhibit 6: International patient revenue forecast



Sources: BDMS; FSSIA estimates

Exhibit 7: BDMS – 1Q24 results preview

THB m) THB m m) THB m		1Q23	2Q23	3Q23	4Q23	1Q24E	Cha	nge	2023	2024E	Change
Sales 24,313 24,372 26,689 26,729 26,883 1 11 102,110 112,311 10 -Hospital revenue 23,084 23,141 25,579 25,583 1 11 97,077 106,575 10 -Oher revenue 1,222 1,227 1,344 1,230 (6,050) 1 9 (63,412) (64,93) 9 Gross profit 9,191 8,404 1,230 (10,337) 10,377 0 13 8,869 4,279 11 SGA (4,633) (4,674) (5,164) (5,161) (17) 11,98,069 (21,544) 9 Operating profit 4,552 52 0 102 173 110 (37) Interest income 12 5 7 19 19 0 55 43 46 10 Interest income 12 5 7 19 19 0 102 173 110 137 Interest i											<u> </u>
- Other revenue 1.229 1.229 1.229 1.232 1.236 1.290 (4) 5 5.034 5.458 8 COGS (nd depreciation) (15.122) (15.432) (16.469) (16.369) (16.506) 1 9 (63.412) (69.333) 9 SGAA (4.633) (4.673) (5.106) (5.101) (5.101) (11 (19.006) (21.504) 9 Operating profit* 4.683 4.064 55 7 19 19 0 55 4.3 4.8 10 Interest income 26 4.8 4.83 5.057 5.051 5.161 1 16 18.583 2.1,31 14 Income Tax (160) (162) (10.25) (10.30) (10.32) (17.3) 17 3.755 1.611 1 16 14.363 2.1,31 14 Income Tax (180) (162) (10.30) (10.20) (10.30) 1.37 1.63.3 1.43 14 <td< td=""><td>Sales</td><td>. /</td><td>. /</td><td>. ,</td><td>. /</td><td></td><td></td><td></td><td>. ,</td><td>. ,</td><td></td></td<>	Sales	. /	. /	. ,	. /				. ,	. ,	
COGS (not depreciation) (15,122) (15,423) (16,489) (16,506) 1 9 (63,412) (60,33) 9 Gross profit 9,191 8,940 10,237 10,337 10,377 0 13 38,688 42,979 11 SGAA (4,633) (4,876) (5,106) (5,1191) (5,116) (1) 11 (19,806) (21,504) 9 Operating profit 4,558 4,064 5,124 5,146 5,216 1 14 18,892 21,475 14 Net other income 12 5 7 19 19 0 55 43 48 10 Interest expense (164) (122) (126) 0 (23) (547) (501) (6) Associates 34 13 21 22 22 0 (37) 89 98 10 Minority interest (116) (120) (10.33) (142) 16 14,375 16,413 14 Decreprofit 3,470 3,063 3,890 3,952 4,008<	- Hospital revenue	23,084	23,141	25,473	25,379	25,593	1	11	97,077	106,875	10
COGS (not depreciation) (15,122) (15,423) (16,489) (16,506) 1 9 (63,412) (60,33) 9 Gross profit 9,191 8,940 10,237 10,337 10,377 0 13 38,688 42,979 11 SGAA (4,633) (4,876) (5,106) (5,1191) (5,116) (1) 11 (19,806) (21,504) 9 Operating profit 4,558 4,064 5,124 5,146 5,216 1 14 18,892 21,475 14 Net other income 12 5 7 19 19 0 55 43 48 10 Interest expense (164) (122) (126) 0 (23) (547) (501) (6) Associates 34 13 21 22 22 0 (37) 89 98 10 Minority interest (116) (120) (10.33) (142) 16 14,375 16,413 14 Decreprofit 3,470 3,063 3,890 3,952 4,008<	•						(4)				
Gross sprofit 9,191 8,440 10,230 10,337 0 13 38,688 42,979 11 SG&A (4,633) (4,873) (5,106) (5,111) (5,161) (1) 11 (19,806) (21,504) 9 Operating profit ¹⁰ 4,558 4,064 5,124 5,144 5,161 1 14 18,892 21,475 14 Net other income 28 48 48 52 52 0 102 173 310 (37) Interest income 28 48 48 5057 5,091 5,161 1 16 18,563 21,131 14 Income Tax (800) (1025) (10,305 (10,305) (17) 16 18,563 21,131 14 Income Tax (880) (163) (123) (142) 16 22 (520) 13 Associates 3,470 3,063 3,890 3,952 4,008 1 16 14,375	COGS (incl depreciation)							9	(63,412)	(69,333)	9
SSAA (4,873) (4,876) (5,106) (5,111) (1) 17 (19,808) (21,504) 9 Operating profit ¹⁰ 4,558 4,064 5,124 5,146 5,216 1 14 118,892 21,475 14 Net other income 12 5 7 19 19 0 55 43 48 10 Interest spense (164) (134) (122) (126) (126) 0 0223 (547) (501) (6) (7) (1) (7) (7) <t< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td>0</td><td>13</td><td></td><td></td><td>11</td></t<>							0	13			11
Operating profit* 4,558 4,064 5,124 5,124 5,146 5,216 1 14 18,892 21,475 14 Net other income 12 5 7 19 19 0 55 43 48 70 Interest income 26 48 48 52 52 0 102 173 110 (37) Interest expense (164) (134) (122) (126) (126) 0 (23) (547) (501) (8) Pretax profit 4,422 3,983 5,087 5,614 1 16 18,563 21,131 Associates 3.4 13 21 22 20 0 377 89 98 10 Minority interest (116) (120) (163) (1123) (112) 16 14,375 16,413 14 Custandinaries, GW & FX Reported net profit 3,470 3,693 3,890 3,852 4,008 1		(4,633)	(4,876)	(5,106)	(5,191)	(5,161)	(1)	11	(19,806)	(21,504)	9
Interest income 26 48 48 52 52 0 102 173 110 (37) Interest expense (164) (134) (122) (126) (126) 0 (23) (547) (501) (6) Protax profit 4432 3.983 5.067 5.091 5.161 1 16 16.863 2.1.13 14 Income Tax (800) (812) (1.025) (1.033) (1.032) (10) 173 80 98 10 Minority interest (116) (120) (163) 11.22 22 0 (37) 89 98 10 Minority interest (116) (120) (163) 11.23 (142) 16 122 (522) (590) 13 Core profit 3.470 3.063 3.890 3.852 4.008 1 16 14.375 16.413 14 Outstanding shares (m) 15.892 15.892 15.892 0.25 1<	Operating profit ¹⁾	,	,	,	,	,		14	,	,	14
Interest expense (164) (134) (122) (126) (126) 0 (23) (547) (501) (8) Preta profit 4.432 3.983 5.057 5.091 (1.032) (11 1 16 13.656 21,131 144 Income Tax: (800) (812) (1.032) (11,032) (11)7 (3.755) (4.262) 133 Associates 34 13 21 22 22 0 (37) 89 98 10 Minority interest (116) (120) (163) (123) (142) 16 22 (522) (590) 13 Core profit 3,470 3,083 3,890 3,952 4,008 1 16 14,375 16,413 14 Core profit 3,470 3,063 3,890 3,952 15,892 15 0 0 15 16 14,375 16,413 14 Outstanding shares (m) 15,892 15,892 15,892 15,892 15,892 0 0 15 16 16 14 </td <td>Net other income</td> <td>12</td> <td>5</td> <td>7</td> <td>19</td> <td>19</td> <td>0</td> <td>55</td> <td>43</td> <td>48</td> <td>10</td>	Net other income	12	5	7	19	19	0	55	43	48	10
Pretax profit 4,432 3,983 5,057 5,091 5,161 1 16 18,563 21,131 14 Income Tax (880) (912) (1,025) (1,033) (1,032) (1) 17 (3,755) (4,226) 13 Associates 34 13 21 22 20 (37) 89 98 10 Minority interest (116) (120) (163) (123) (142) 16 22 (522) (590) 13 Core profit 3,470 3,063 3,890 3,952 4,008 1 16 14,375 16,413 14 Core profit 3,470 3,063 3,890 3,952 4,008 1 16 14,375 16,413 14 Outstanding shares (m) 15,892 15,892 15,892 0.25 0.25 1 16 0.90 1.03 14 COGS (excl depreciation) 13,986 14,999 14,866 14,989 1	Interest income	26	48	48	52	52	0	102	173	110	(37)
Pretax profit 4,432 3,833 5,057 5,091 5,161 f f6 18,563 21,131 14 Income Tax (800) (812) (1,025) (1,033) (1,032) (11 17 (3,755) (4,226) 13 Associates 34 13 21 22 20 037 89 98 10 Minority interest (116) (120) (163) (123) (142) 16 22 (520) (590) 13 Core profit 3,470 3,063 3,890 3,952 4,008 1 16 14,375 16,413 14 Coustanding shares (m) 15,892 15,892 15,892 15,892 0 0 0 15,892 16 9 1,433 14 EPS (THB) 0.22 0.19 0.24 0.25 0.25 1 16 0.90 1.03 14 COGS (excl depreciation) 13,693 13,986 14,999 14,886 </td <td>Interest expense</td> <td>(164)</td> <td>(134)</td> <td>(122)</td> <td>(126)</td> <td>(126)</td> <td>0</td> <td>(23)</td> <td>(547)</td> <td>(501)</td> <td>(8)</td>	Interest expense	(164)	(134)	(122)	(126)	(126)	0	(23)	(547)	(501)	(8)
Associates 34 13 21 22 22 0 (37) 89 99 10 Minority interest (116) (120) (163) (123) (142) 76 22 (522) (590) 13 Core profit 3,470 3,063 3,890 3,952 4,008 1 16 14,375 16,413 14 Extraordinaries, GW & FX 0	Pretax profit	4,432	3,983	5,057	5,091	5,161	1		18,563	21,131	14
Associates 34 13 21 22 22 0 (37) 89 98 10 Minority interest (116) (120) (123) (142) 16 22 (522) (580) 13 Core profit 3,470 3,063 3,890 3,952 4,008 1 16 14,375 16,413 14 Extraordinaries, GW & FX 0 0 0 0 0 0 0 0 0 0 Reported net profit 3,470 3,663 3,890 3,952 15,892 0.08 1 16 14,375 16,413 14 Outstanding shares (m) 15,892 15,892 15,892 15,892 0.25 1 16 0.90 1.03 14 EPS (THB) 0.22 0.19 0.24 0.25 0.25 1 16 0.90 1.03 14 COGS (excl depreciation) 13,693 13,986 14,999 14,886 14,989 1 9 57,564 63,090 10 Depreciation 1,429	Income Tax	(880)	(812)	(1,025)	(1,038)	(1,032)	(1)	17	(3,755)	(4,226)	13
Core profit Extraordinaries, GW & FX 3,470 3,063 3,890 3,952 4,008 1 16 14,375 16,413 14 Reported net profit 3,470 3,063 3,890 3,952 4,008 1 16 14,375 16,413 14 Outstanding shares (m) 15,892 15,892 15,892 15,892 0 0 15,892 15,892 0 Core EPS (THB) 0.22 0.19 0.24 0.25 0.25 1 16 0.90 1.03 14 COGS (excl depreciation) 13,693 13,986 14,999 14,886 14,999 1 9 57,564 63,090 10 Depreciation 1,429 1,446 1,470 1,503 1,518 1 6 5,848 6,243 7 EBITDA ²¹ 5,987 5,510 6,544 6,649 6,734 1 12 24,740 27,717 12 S6&A/Revenue 19 19 19 19	Associates	34	13	21	22	22		(37)	89	98	10
Extraordinaries, GW & FX Reported net profit 3,470 3,683 3,890 3,952 4,008 1 16 14,375 16,413 14 Outstanding shares (m) 15,892 15,892 15,892 15,892 0 0 15,892 15,892 0 0 15,892 15,892 0 0 15,892 15,892 0 0 15,892 15,892 0 0 15,892 15,892 0 0 15,892 16,893 14,999 1 9 57,564 63,090 10 Depreciation 13,493 13,986 14,999 1 9 57,564 63,090 10 Depreciation 13,493 13,486 14,999 1 9 57,564 63,090 10 12 24,740 27,717 12 Key ratios (% (%) (%) (%) (%) (%) (%) (%) (%) (%) (%) (%) (%) (%) (%) (%) (%)	Minority interest	(116)	(120)	(163)	(123)	(142)	16		(522)	(590)	13
Reported net profit 3,470 3,063 3,890 3,952 4,008 1 16 14,375 16,413 14 Outstanding shares (m) 15,892 15,892 15,892 15,892 0 0 15,892 15,892 0 0 15,892 15,892 0 0 15,892 15,892 0 0 15,892 15,892 0 0 0 15,892 10 0 0 15,892 15,892 0 0 15,892 15,892 0 0 15,892 15,892 0 0 15,892 10 14 COGS (excl depreciation) 13,693 13,986 14,999 14,886 14,989 1 9 57,564 63,090 10 12 24,740 27,717 12 EBITDA Ra 38 37 38 38.7 38.6 (0) 1 38 38 0 SG&A/Revenue 19 10 19 19 00 0 1	Core profit	3,470	3,063		3,952	4,008	1	16		16,413	14
Outstanding shares (m) 15,892 15,892 15,892 15,892 15,892 0 0 15,892 15,892 0 Core EPS (THB) 0.22 0.19 0.24 0.25 0.25 1 16 0.90 1.03 14 EPS (THB) 0.22 0.19 0.24 0.25 0.25 1 16 0.90 1.03 14 COGS (excl depreciation) 13,693 13,896 14,999 14,886 14,989 1 9 57,564 63,090 10 Depreciation 1,429 1,446 1,470 1,503 1,518 1 6 5,848 6,243 7 EBITDA ²³ 5,987 5,510 6,594 6,649 6,734 1 12 24,740 27,717 12 Key ratios (%) 1 13 38 0	-										
Outstanding shares (m) 15,892 15,892 15,892 15,892 15,892 0 0 15,892 15,892 0 Core EPS (THB) 0.22 0.19 0.24 0.25 0.25 1 16 0.90 1.03 14 EPS (THB) 0.22 0.19 0.24 0.25 0.25 1 16 0.90 1.03 14 COGS (excl depreciation) 13,683 13,986 14,999 14,886 14,989 1 9 57,564 63,090 10 Depreciation 1,429 1,446 1,470 1,503 1,518 1 6 5,848 6,243 7 EBITDA ² 5,987 5,510 6,594 6,649 6,734 1 12 24,740 27,717 12 Key ratios (%) (%) (%) (%) (%) (%) (%) (%) (%) (%) (%) (%) (%) (%) (%) 138 38 0		3,470	3,063	3,890	3,952	4,008	1	16	14,375	16,413	14
Core EPS (THB) 0.22 0.19 0.24 0.25 0.25 1 16 0.90 1.03 14 EPS (THB) 0.22 0.19 0.24 0.25 0.25 1 16 0.90 1.03 14 COGS (excl depreciation) 13,693 13,986 14,999 14,886 14,989 1 9 57,564 63,090 10 Depreciation 1,429 1,446 1,470 1,503 1,518 1 6 5,848 6,243 7 EBITDA ²¹ 5,987 5,510 6,594 6,649 6,734 1 12 24,740 27,717 12 Key ratios (%) (%) (%) (%) (%) (ppt) (ppt) (%) (ppt) Gross margin 38 37 38 38.7 38.6 (0) 1 38 38 0 SG&A/Revenue 19 20 19 19 19 00 24 25					,				,	,	
EPS (THB)0.220.190.240.250.251160.901.0314COGS (excl depreciation)13,69313,98614,99914,88614,9891957,56463,09010Depreciation1,4291,4461,4701,5031,518165,8486,2437EBITDA ²¹ 5,9875,5106,5946,6496,73411224,74027,71712Key ratios(%)<	Outstanding shares (m)	15,892	15,892	15,892	15,892	15,892	0	0	15,892	15,892	0
COGS (excl depreciation) 13,893 13,986 14,999 14,886 14,989 1 9 57,564 63,090 10 Depreciation 1,429 1,446 1,470 1,503 1,518 1 6 5,848 6,243 7 EBITDA ²⁾ 5,987 5,510 6,594 6,649 6,734 1 12 24,740 27,717 12 Key ratios (%) (%) (%) (%) (%) (%) (ppt) (ppt) (%) (ppt) Gross margin 38 37 38 38.7 38.6 (0) 1 38 38 0 SGA/Revenue 19 20 19 19 19 (0) 0 19 19 (0) EBITDA margin 25 23 25 25 26 0 1 14 15 1 Operating stats (%) (%) (%) (%) (%) (%) (%) 1 1 15 1 1 1 1 1 1 15 <th< td=""><td>Core EPS (THB)</td><td>0.22</td><td>0.19</td><td>0.24</td><td>0.25</td><td>0.25</td><td>1</td><td>16</td><td>0.90</td><td>1.03</td><td>14</td></th<>	Core EPS (THB)	0.22	0.19	0.24	0.25	0.25	1	16	0.90	1.03	14
Depreciation 1,429 1,446 1,470 1,503 1,518 1 6 5,848 6,243 7 EBITDA ² 5,987 5,510 6,594 6,649 6,734 1 12 24,740 27,717 12 Key ratios (%) (%) (%) (%) (%) (%) (%) (ppt) Gross margin 38 37 38 38.7 38.6 (0) 1 38 38 0 SG&A/Revenue 19 20 19 19 19 (0) 0 19 19 (0) EBITDA margin 25 23 25 25 0 0 1 14 15 1 Operating stats (%) (%) (%) (%) (%) 1 1 1 1 OPD revenue growth y-y 11 10 14 14 15 1 1 1 1 1 1 1 1 <t< td=""><td>EPS (THB)</td><td>0.22</td><td>0.19</td><td>0.24</td><td>0.25</td><td>0.25</td><td>1</td><td>16</td><td>0.90</td><td>1.03</td><td>14</td></t<>	EPS (THB)	0.22	0.19	0.24	0.25	0.25	1	16	0.90	1.03	14
Depreciation 1,429 1,446 1,470 1,503 1,518 1 6 5,848 6,243 7 EBITDA ² 5,987 5,510 6,594 6,649 6,734 1 12 24,740 27,717 12 Key ratios (%)	COGS (excl depreciation)	13 693	13 986	14 999	14 886	14 989	1	9	57 564	63 090	10
EBITDA ² 5,987 5,510 6,594 6,649 6,734 1 12 24,740 27,717 12 Key ratios (%) (%) (%) (%) (%) (%) (ppt) (ppt) (%) (%) (ppt) Gross margin 38 37 38 38.7 38.6 (0) 1 38 38 0 SG&A/Revenue 19 20 19 19 19 (0) 0 19 19 (0) EBITDA margin 25 23 25 25 0 0 24 25 0 Net profit margin 14 13 15 15 0 1 14 15 1 OPD revenue growth y-y 11 10 14 14 15 1											
Key ratios (%) (%) (%) (%) (ppt) (ppt) (%) (%) (ppt) Gross margin 38 37 38 38.7 38.6 (0) 1 38 38 0 SG&A/Revenue 19 20 19 19 19 (0) 0 19 19 (0) EBITDA margin 25 23 25 25 25 0 0 24 25 0 Net profit margin 14 13 15 15 0 1 14 15 1 OPD revenue growth y-y 11 10 14 14 15 1											
Gross margin 38 37 38 38.7 38.6 (0) 1 38 38 0 SG&A/Revenue 19 20 19 19 19 (0) 0 19 19 (0) EBITDA margin 25 23 25 25 25 0 0 24 25 0 Net profit margin 14 13 15 15 15 0 1 14 15 1 Operating stats (%)		-,	-,	-,	-,	-,				,	
Gross margin 38 37 38 38.7 38.6 (0) 1 38 38 0 SG&A/Revenue 19 20 19 19 19 (0) 0 19 19 (0) EBITDA margin 25 23 25 25 25 0 0 24 25 0 Net profit margin 14 13 15 15 15 0 1 14 15 1 Operating stats (%)	Key ratios	(%)	(%)	(%)	(%)	(%)	(ppt)	(ppt)	(%)	(%)	(ppt)
EBITDA margin Net profit margin 25 23 25 25 25 0 0 24 25 0 Operating stats (%)	Gross margin	38	37	38	38.7	38.6		1	38	38	
Net profit margin 14 13 15 15 0 1 14 15 1 Operating stats (%)	SG&A/Revenue	19	20	19	19	19	(0)	0	19	19	(0)
Operating stats(%)(%)(%)OPD revenue growth y-y111014OPD volume growth y-y(7)00OPD revenue per head growth y-y201014IPD revenue growth y-y(2)10915IPD volume growth y-y336020IPD revenue per head growth y-y(26)(31)(9)Thai revenue growth y-y(6)7910	EBITDA margin	25	23	25	25	25	0	0	24	25	0
OPD revenue growth y-y 11 10 14 OPD volume growth y-y (7) 0 0 OPD revenue per head growth y-y 20 10 14 IPD revenue growth y-y (2) 10 9 15 IPD revenue growth y-y 33 60 20 IPD revenue per head growth y-y (26) (31) (9) Thai revenue growth y-y (6) 7 9 10	Net profit margin	14	13	15	15	15	0	1	14	15	1
OPD revenue growth y-y 11 10 14 OPD volume growth y-y (7) 0 0 OPD revenue per head growth y-y 20 10 14 IPD revenue growth y-y (2) 10 9 15 IPD revenue growth y-y 33 60 20 IPD revenue per head growth y-y (26) (31) (9) Thai revenue growth y-y (6) 7 9 10	Operating stats	(%)	(%)	(%)	(%)						
OPD volume growth y-y(7)00OPD revenue per head growth y-y201014IPD revenue growth y-y(2)10915IPD volume growth y-y336020IPD revenue per head growth y-y(26)(31)(9)Thai revenue growth y-y(6)7910	OPD revenue growth y-y				. ,						
OPD revenue per head growth y-y201014IPD revenue growth y-y(2)10915IPD volume growth y-y336020IPD revenue per head growth y-y(26)(31)(9)Thai revenue growth y-y(6)7910		(7)									
IPD volume growth y-y336020IPD revenue per head growth y-y(26)(31)(9)Thai revenue growth y-y(6)7910											
IPD revenue per head growth y-y(26)(31)(9)Thai revenue growth y-y(6)7910	IPD revenue growth y-y	(2)	10	9	15						
Thai revenue growth y-y (6) 7 9 10	IPD volume growth y-y	33	60	20							
	IPD revenue per head growth y-y	(26)	(31)	(9)							
	Thai revenue growth y-y	(6)	7	9	10						
	International revenue growth y-y										

Note: 1) Gross profit calculated by revenue – COGS including depreciation; 2) EBITDA calculated by operating profit + operating income – depreciation Sources : BDMS; FSSIA estimates

Exhibit 8: One-year prospective P/E band



Exhibit 9: One-year prospective P/BV band

BDMS PBV (x)

Sources: Bloomberg; FSSIA estimates



Sources: Bloomberg; FSSIA estimates

Exhibit 10: Peer comparisons as of 9 April 2024

Company	BBG	Rec		Share price)	Market	Pl	E	RO)E	PB	SV	EV/ EB	ITDA
			Current	Target	Upside	Сар	24E	25E	24E	25E	24E	25E	24E	25E
			(LCY)	(LCY)	(%)	(USD m)	(x)	(x)	(%)	(%)	(x)	(x)	(x)	(x)
Thailand														
Bangkok Dusit Med Service	BDMS TB	BUY	28.50	35.00	22.8	12,458	27.6	25.3	16.8	17.3	4.5	4.2	16.7	15.2
Bumrungrad Hospital	BH TB	BUY	232.00	305.00	31.5	5,073	25.0	23.5	28.8	26.8	6.7	5.9	16.5	15.3
Bangkok Chain Hospital	BCH TB	BUY	20.60	26.00	26.2	1,413	27.6	24.4	14.2	14.9	3.8	3.5	15.0	13.2
Chularat Hospital	CHG TB	BUY	2.92	3.90	33.6	884	24.7	21.6	16.7	17.7	4.0	3.7	14.4	12.7
Praram 9 Hospital	PR9 TB	BUY	19.40	24.00	23.7	420	23.3	21.2	12.4	12.6	2.8	2.6	11.7	10.4
Thonburi Healthcare Group	THG TB	HOLD	41.25	44.00	6.7	962	42.9	35.8	7.8	9.1	3.3	3.2	18.6	16.8
Ramkhamhaeng Hospital	RAM TB	BUY	30.50	46.00	50.8	1,007	20.9	18.1	9.3	10.2	1.9	1.8	25.7	20.5
Rajthanee Hospital	RJH TB	n/a	24.70	n/a	n/a	203	17.4	17.9	19.1	18.8	4.9	3.2	12.9	12.2
Ekachai Medical Care	EKH TB	n/a	7.65	n/a	n/a	149	19.0	18.7	14.6	13.4	5.6	2.5	10.4	9.7
Thailand average						22,568	25.4	22.9	15.5	15.6	4.2	3.4	15.8	14.0
Regional														
Ramsay Health Care	RHC AU	n/a	53.51	n/a	n/a	8,138	36.1	40.0	8.6	7.1	3.0	2.9	11.7	11.0
Ihh Healthcare Bhd	IHH SP	n/a	1.72	n/a	n/a	11,258	33.5	31.0	6.3	5.9	2.3	1.9	14.1	13.3
Ryman Healthcare	RYM NZ	n/a	4.48	n/a	n/a	1,865	8.9	11.2	7.5	7.0	1.0	0.6	11.8	14.9
Apollo Hospitals Enterprise	APHS IN	n/a	6,505	n/a	n/a	11,233	111.2	95.8	13.8	14.7	25.7	14.5	45.7	40.1
Kpj Healthcare Berhad	KPJ MK	n/a	1.91	n/a	n/a	1,756	36.0	28.5	10.2	11.6	4.3	3.6	15.2	13.8
Raffles Medical Group	RFMD SP	n/a	1.03	n/a	n/a	1,419	21.5	26.4	8.6	7.1	2.2	1.9	10.6	12.5
Mitra Keluarga Karyasehat	MIKA IJ	n/a	2,820	n/a	n/a	2,530	41.6	35.7	17.1	17.7	8.3	6.7	25.6	22.5
Aier Eye Hospital Group	300015 CH	n/a	13.01	n/a	n/a	16,781	34.4	27.3	18.3	19.6	13.9	6.0	20.3	16.3
Regional average						54,980	40.4	37.0	11.3	11.3	7.6	4.8	19.4	18.0
Overall average						77,548	32.4	29.6	13.5	13.6	5.8	4.0	17.5	15.9

Sources: Bloomberg; FSSIA estimates

Financial Statements

Bangkok Dusit Medical Services

Profit and Loss (THB m) Year Ending Dec	2022	2023	2024E	2025E	2026E
Revenue	92,968	102,110	112,311	121,304	131,022
Cost of goods sold	(58,329)	(63,412)	(69,333)	(74,787)	(80,610
Gross profit	34,638	38,698	42,979	46,518	50,413
Other operating income	-	-	-	-	
Operating costs	(17,655)	(19,806)	(21,504)	(23,104)	(24,824
Operating EBITDA	22,933	24,740	27,717	30,179	32,859
Depreciation	(5,950)	(5,848)	(6,243)	(6,766)	(7,271
Goodwill amortisation	-	-	-	-	
Operating EBIT	16,984	18,892	21,475	23,413	25,588
Net financing costs	(552)	(373)	(391)	(358)	(288
Associates	42	89	98	108	119
Recurring non-operating income	50	133	146	161	177
Non-recurring items	0	0	0	0	(
Profit before tax	16,481	18,652	21,230	23,216	25,477
Тах	(3,227)	(3,755)	(4,226)	(4,622)	(5,072
Profit after tax	13,254	14,897	17,003	18,595	20,406
Minority interests	(648)	(522)	(590)	(667)	(753
Preferred dividends	-	-	-	-	
Other items	-	-	-	-	
Reported net profit	12,606	14,375	16,413	17,928	19,652
Non-recurring items & goodwill (net)	0	0	0	0	(
Recurring net profit	12,606	14,375	16,413	17,928	19,652
Per share (THB)					
Recurring EPS *	0.79	0.90	1.03	1.13	1.24
Reported EPS	0.79	0.90	1.03	1.13	1.24
DPS	0.50	0.65	0.70	0.72	0.79
Diluted shares (used to calculate per share data)	15,892	15,892	15,892	15,892	15,892
Growth					
Revenue (%)	23.1	9.8	10.0	8.0	8.0
Operating EBITDA (%)	32.2	7.9	12.0	8.9	8.9
Operating EBIT (%)	54.1	11.2	13.7	9.0	9.3
Recurring EPS (%)	63.0	14.0	14.2	9.2	9.6
Reported EPS (%)	58.8	14.0	14.2	9.2	9.6
Operating performance					
Gross margin inc. depreciation (%)	37.3	37.9	38.3	38.3	38.5
Gross margin exc. depreciation (%)	43.7	43.6	43.8	43.9	44.0
Operating EBITDA margin (%)	24.7	24.2	24.7	24.9	25.1
Operating EBIT margin (%)	18.3	18.5	19.1	19.3	19.5
Net margin (%)	13.6	14.1	14.6	14.8	15.0
Effective tax rate (%)	19.6	20.2	20.0	20.0	20.0
Dividend payout on recurring profit (%)	63.0	71.9	67.8	64.1	63.9
Interest cover (X)	30.8	51.0	55.3	65.9	89.5
Inventory days	14.7	14.7	14.7	14.8	14.8
Debtor days	38.5	39.4	37.6	34.8	32.2
Creditor days	39.1	41.5	41.8	42.2	42.2
Operating ROIC (%)	15.8	16.1	17.5	18.6	42.2
ROIC (%)	12.7	13.1	14.4	15.3	16.5
ROE (%)	14.5	15.5	16.8	17.3	17.8
ROA (%)	14.5	10.7	11.8	12.2	12.7
* Pre-exceptional, pre-goodwill and fully diluted	10.1	10.7	11.0	12.2	12.1
Revenue by Division (THB m)	2022	2023	2024E	2025E	2026E
	2022	2023	2024	2025	20201
	07 000	70 000	70 700	00 7 1 1	
Thai patient revenue International patient revenue	67,286 21,248	70,866 26,211	76,733 30,142	82,741 32,855	89,217 35,812

Sources: Bangkok Dusit Medical Services; FSSIA estimates

Financial Statements

Bangkok Dusit Medical Services

cash Flow (THB m) Year Ending Dec	2022	2023	2024E	2025E	20265
Recurring net profit	12,606	14,375	16,413	17,928	19,652
Depreciation	5,950	5,848	6,243	6,766	7,271
ssociates & minorities	-	-	-	-	
Other non-cash items	1,275	1,203	590	667	753
change in working capital	720	161	1,291	1,142	1,234
ash flow from operations	20,551	21,588	24,537	26,503	28,910
Capex - maintenance	(14,953)	(11,612)	(11,231)	(9,704)	(10,482
Capex - new investment	-	-	-	-	
let acquisitions & disposals	(386)	(290)	0	0	(
Other investments (net)	-	-	-	-	(40,400
cash flow from investing	(15,340)	(11,902)	(11,231)	(9,704)	(10,482
lividends paid	(7,943)	(10,343)	(11,124)	(11,489)	(12,550
quity finance	0	0	0	0	(500
bebt finance	4,764 299	(5,460) 612	(500) 0	(500) 0	(500
Other financing cash flows					
cash flow from financing Ion-recurring cash flows	(2,880)	(15,190)	(11,624)	(11,989)	(13,050
	- 0	- 0	- 0	- 0	(
)ther adjustments let other adjustments	0	0	0	0	
lovement in cash	2,330	(5,505)	1,681	4,810	5,379
ree cash flow to firm (FCFF)	5,842.84	10,232.29	13,806.49	17,285.67	18,901.18
ree cash flow to equity (FCFE)	10,273.66	4,838.23	12,805.74	16,298.92	17,928.43
	10,210.00	1,000.20	12,000.14	10,200.02	11,020.4
Per share (THB)		0.01	0.07	4.00	
CFF per share	0.37	0.64	0.87	1.09	1.19
CFE per share Recurring cash flow per share	0.65 1.25	0.30 1.35	0.81 1.46	1.03 1.60	1.1: 1.74
	1.20	1.00			1.7
alance Sheet (THB m) Year Ending Dec	2022	2023	2024E	2025E	20265
angible fixed assets (gross)	155,412	165,315	176,546	186,250	196,73
ess: Accumulated depreciation	(63,503)	(67,642)	(73,884)	(80,650)	(87,921
angible fixed assets (net)	91,909	97,673	102,662	105,600	108,81
ntangible fixed assets (net)	19,160	19,376	19,376	19,376	19,37
ong-term financial assets	-	-	-	-	
nvest. in associates & subsidiaries	1,986	2,276	2,276	2,276	2,276
Cash & equivalents	14,972	9,467	11,148	15,958	21,337
/C receivable	10,484	11,558	11,558	11,558	11,55
nventories	2,211	2,420	2,652	2,859	3,083
Other current assets	132	101	111	120	13
Current assets	27,799	23,545	25,469	30,495	36,10
Other assets	689	726	726	726	726
otal assets	141,543	143,596	150,508	158,472	167,29
common equity	89,879	95,242	100,531	106,970	114,072
linorities etc.	3,834	3,630	4,220	4,887	5,64
otal shareholders' equity	93,713	98,872	104,752	111,857	119,71
ong term debt	23,062	18,134	17,634	17,134	16,634
Other long-term liabilities	10,032	10,973	10,973	10,973	10,973
ong-term liabilities	33,094	29,107	28,607	28,107	27,60
/C payable	6,176	6,901	7,564	8,155	8,79
short term debt	532	0	0	0	
Other current liabilities	8,028	8,715	9,586	10,353	11,18
Current liabilities	14,736	15,616	17,149	18,508	19,97
otal liabilities and shareholders' equity	141,543	143,596	150,508	158,472	167,29
let working capital	(1,377)	(1,538)	(2,828)	(3,971)	(5,205
nvested capital Includes convertibles and preferred stock which is being	112,367 treated as debt	118,513	122,211	124,006	125,984
	udaleu as uebl				
er share (THB)					
ook value per share	5.66	5.99	6.33	6.73	7.1
angible book value per share	4.45	4.77	5.11	5.51	5.9
inancial strength					
let debt/equity (%)	9.2	8.8	6.2	1.1	(3.9
let debt/total assets (%)	6.1	6.0	4.3	0.7	(2.8
Current ratio (x)	1.9	1.5	1.5	1.6	1.8
F interest cover (x)	19.6	14.0	33.7	46.6	63.3
	2022	2023	2024E	2025E	2026
aluation		31.5	27.6	25.3	23.
	35.9			31.0	28.
'aluation Recurring P/E (x) *	35.9 44.1	38.7	33.9	01.0	
aluation		38.7 31.5	33.9 27.6	25.3	
aluation tecurring P/E (x) * tecurring P/E @ target price (x) * teported P/E (x)	44.1	31.5			23.
'aluation Recurring P/E (x) * Recurring P/E @ target price (x) *	44.1 35.9		27.6	25.3	23.0 2.8 4.0
Aduation Accurring P/E (x) * Accurring P/E @ target price (x) * Accurring P/E (x) Accurring P/E (x) Accurring P/E (x) Accurring P/E (x) * Accurring P/E (x) * Accur	44.1 35.9 1.8	31.5 2.3	27.6 2.5	25.3 2.5	23.0 2.8
'aluation Recurring P/E (x) * Recurring P/E @ target price (x) * teported P/E (x) vividend yield (%) trice/book (x)	44.1 35.9 1.8 5.0	31.5 2.3 4.8	27.6 2.5 4.5	25.3 2.5 4.2	23.0 2.8 4.0
aluation lecurring P/E (x) * lecurring P/E @ target price (x) * leported P/E (x) lividend yield (%) rice/book (x) rice/tangible book (x)	44.1 35.9 1.8 5.0 6.4	31.5 2.3 4.8 6.0	27.6 2.5 4.5 5.6	25.3 2.5 4.2 5.2	23. 2. 4. 4.

Sources: Bangkok Dusit Medical Services; FSSIA estimates



Bangkok Dusit Medical Serv (BDMS TB)

FSSIA ESG rating

 \star \star \star \star

Exhibit 11: FSSIA ESG score implication

Exhibit 11: FSSIA	ESG score	implication 74.00 /100
Rating	Score	Implication
****	>79-100	Leading its industry peers in managing the most significant ESG risks which not only better cost efficiency but also lead to higher profitability.
****	>59-79	A mixed track record of managing the most significant ESG risks and opportunities relative to industry peers.
***	>39-59	Relevant ESG materiality matrix has been constructively addressed, well-managed and incorporated into day-to-day operations, in which targets and achievements are evaluated annually.
**	>19-39	Relevant ESG materiality matrix has been identified with key management in charge for progress to be followed up on and to provide intensive disclosure. Most targets are conventional and achievable.
*	1-19	The company has adopted the United Nations Sustainable Development Goals (UN SDGs), established sustainability management guidelines and fully complies with regulations or ESG suggested guidance from related organizations such as the SET and SEC.

Sources: FSSIA estimates

Exhibit 12: ESG – peer comparison

	FSSIA			Domes	stic ratings	\$				Glo	bal ratings			Bloomberg		
	ESG score	DJSI	SET THSI	THSI	CG score	AGM level	Thai CAC	Morningstar ESG risk	ESG Book	MSCI	Moody's	Refinitiv	S&P Global	ESG score	Disclosure score	
SET100	69.20	5.34	4.40	4.40	4.76	4.65	3.84	Medium	51.76	BBB	20.87	58.72	63.91	3.72	28.17	
Coverage	67.12	5.11	4.15	4.17	4.83	4.71	3.53	Medium	52.04	BB	16.97	56.85	62.09	3.40	31.94	
BCH	39.71				4.00	5.00	Certified	High	48.21			27.19	18.00	3.52	47.60	
BDMS	74.00	Y	Y	Y	5.00	4.00		Medium	61.06	AA	34.00	59.83	72.00	3.45	58.92	
BH	51.21				4.00	4.00		Medium	64.29	Α	29.00	59.03	27.00	5.08	47.79	
CHG	38.25				4.00	5.00		High	55.35			59.57	21.00	2.34	50.24	
PR9	54.08		Y	Y	5.00	5.00	Certified	High	71.12			62.39		2.43	37.90	
PRINC	18.00				4.00	4.00	Certified									
RAM	11.75				3.00			High								
THG	18.75				5.00	5.00		High								
VIBHA	20.88				4.00	3.00	Declared	High					17.00			

Sources: SETTRADE.com; FSSIA's compilation

Exhibit 13: ESG score by Bloomberg

FY ending Dec 31	FY 2015	FY 2016	FY 2017	FY 2018	FY 2019	FY 2020	FY 2021	FY 2022
ESG financial materiality scores - ESG score	1.08	1.05	2.21	2.76	3.74	3.77	3.76	3.45
BESG environmental pillar score	0.00	0.00	2.04	4.49	4.17	3.84	3.24	2.25
BESG social pillar score	0.14	0.14	1.24	1.48	3.40	3.53	3.54	3.59
BESG governance pillar score	4.56	4.40	4.37	4.19	4.03	4.13	4.51	4.12
ESG disclosure score	32.33	32.33	46.90	47.34	57.35	57.69	58.34	58.92
Environmental disclosure score	0.00	0.00	22.74	24.07	52.31	52.31	54.27	56.00
Social disclosure score	13.21	13.21	34.22	34.22	36.03	37.06	37.06	37.06
Governance disclosure score	83.59	83.59	83.59	83.59	83.59	83.59	83.59	83.59
Environmental								
Emissions reduction initiatives	No							
Climate change policy	No	No	No	No	Yes	Yes	Yes	Yes
Climate change opportunities discussed	No							
Risks of climate change discussed	No							
GHG scope 1	—	—	3	4	9	35	9	34
GHG scope 2 location-based	—	—	91	92	98	94	96	209
GHG Scope 3	—	—	—	—	—	—	—	_
Carbon per unit of production	—	—	—	—	—	—	—	_
Biodiversity policy	No							
Energy efficiency policy	No	No	Yes	Yes	Yes	Yes	Yes	Yes
Total energy consumption	_	_	143	145	152	147	194	497
Renewable energy use	_	_	_	_	_	_	_	5
Electricity used	_	_	143	145	152	147	192	417
Fuel used - natural gas	_	_	_	_	_	_	_	_

Sources: Bloomberg; FSSIA's compilation

Exhibit 14: ESG score by Bloomberg (cont.)

FY ending Dec 31	FY 2015	FY 2016	FY 2017	FY 2018	FY 2019	FY 2020	FY 2021	FY 2022
Fuel used - crude oil/diesel	No							
Waste reduction policy	No	No	No	Yes	Yes	Yes	Yes	Yes
Hazardous waste	—	—	1	2	2	2	3	5
Total waste	—	-	6	7	7	5	9	13
Waste recycled	—	-	0	1	1	0	1	2
Waste sent to landfills				_	_	_	3	5
Environmental supply chain management	No	No	No	No	Yes	Yes	Yes	Yes
Water policy	No	No	No	Yes	Yes	Yes	Yes	Yes
Water consumption	_	_	354	358	388	332	472	754
Social								
Human rights policy	Yes							
Policy against child labor	No	No	No	No	No	Yes	Yes	Yes
Quality assurance and recall policy	No	No	No	No	Yes	Yes	Yes	Yes
Consumer data protection policy	No	No	Yes	Yes	Yes	Yes	Yes	Yes
Equal opportunity policy	Yes							
Gender pay gap breakout	No							
Pct women in workforce	_	—	82	82	82	82	83	83
Pct disabled in workforce	_	—	_	—	—	—	-	-
Business ethics policy	Yes							
Anti-bribery ethics policy	Yes							
Health and safety policy	Yes							
Lost time incident rate - employees	—	—	0	0	0	0	0	1
Total recordable incident rate - employees	—	—	2	2	2	1	1	1
Training policy	Yes							
Fair remuneration policy	No							
Number of employees – CSR	33,456	36,989	37,505	38,803	40,298	36,254	36,344	40,495
Employee turnover pct	_	_	18	19	19	17	16	20
Total hours spent by firm - employee training	568,960	588,890	795,330	547,592	784,625	476,816	437,209	1,417,320
Social supply chain management	No	No	No	No	Yes	Yes	Yes	Yes
Governance								
Board size	15	14	13	14	14	16	18	17
No. of independent directors (ID)	7	6	6	6	6	7	7	7
No. of women on board	2	1	1	1	1	2	2	2
No. of non-executive directors on board	9	7	6	8	9	9	9	9
Company conducts board evaluations	Yes							
No. of board meetings for the year	13	13	14	12	13	12	12	12
Board meeting attendance pct	95	94	98	97	98	98	97	100
Board duration (years)	3	3	3	3	3	3	3	3
Director share ownership guidelines	No							
Age of the youngest director	45	42	43	44	45	46	47	48
Age of the oldest director	83	84	85	86	87	88	89	90
No. of executives / company managers	4	5	5	5	6	7	5	5
No. of female executives	1	1	1	2	1	2	2	2
Executive share ownership guidelines	No							
Size of audit committee	3	3	3	3	3	3	3	3
No. of ID on audit committee	3	3	3	3	3	3	3	3
Audit committee meetings	10	9	10	7	10	6	6	6
Audit meeting attendance %	100	100	100	100	97	100	100	100
Size of compensation committee	4	4	4	4	4	3	3	3
No. of ID on compensation committee	3	3	3	2	2	2	2	2
No. of compensation committee meetings	3	1	4	4	3	4	4	3
Compensation meeting attendance %	100	100	100	100	100	100	100	100
Size of nomination committee	4	4	4	4	4	3	3	3
No. of nomination committee meetings	3	1	4	4	3	4	4	3
Nomination meeting attendance %	100	100	100	100	100	100	100	100
Sustainability governance	100						100	100

Sources: Bloomberg; FSSIA's compilation

Disclaimer for ESG scoring

ESG score	Methodolog	I <u>y</u>			Rating				
The Dow Jones Sustainability Indices (DJSI) By S&P Global	process base from the ann Only the top- inclusion.	ed on the com ual S&P Glob -ranked compa	transparent, rules-based panies' Total Sustainabi al Corporate Sustainabil anies within each industr	lity Scores resulting ity Assessment (CSA). y are selected for	Sustainability A ESG Score of I scoring compa selected from t	Assessment (C ess than 45% ny are disqual he Eligible Un		mpanies with al ESG Score uents of the D	an S&P Globa of the highest JSI indices are
Sustainability Investment List (<u>THSI</u>) by The Stock Exchange of Thailand (<u>SET</u>)	managing bu Candidates r 1) no irregula float of >150 up capital. S 70%; 2) inde wrongdoing r	usiness with tra- must pass the ar trading of th shareholders ome key disqu pendent direc related to CG,	lity in Environmental and ansparency in Governan preemptive criteria, with le board members and e , and combined holding r Julifying criteria include: tors and free float violati social & environmental arnings in red for > 3 yea	ce, updated annually. two crucial conditions: xecutives; and 2) free must be >15% of paid- 1) CG score of below on; 3) executives' impacts; 4) equity in	minimum of 50 during the asse nature of the re <u>SETTHSI Inde</u> capitalization > >0.5% of paid-	% for each inc essment year. elevant industr <u>x</u> is extended THB5b (~USI up capital for a cet capitalisatio	sion, verified dat licator, unless the The scoring will 1 y and materiality from the THSI oc D150b); 2) free fl at least 9 out of 1 on-weighted inde mber of stocks.	e company is be fairly weigh ompanies who oat >20%; and 2 months. The	a part of DJSI ited against the se 1) market d 3) liquidity e SETTHSI
CG Score by Thai Institute of Directors Association (Thai IOD)	annually by t Thailand (SE	he Thai IOD, s	h in sustainable develop with support from the Sto s are from the perspectiv s.	ock Exchange of	Good (80-89), and not rated f equitable treat	3 for Good (70 or scores belo nent of shareh 25%); 4) disclo	ories: 5 for Excel 0-79), 2 for Fair (6 w 50. Weightings nolders (weight 2 sure & transpare	60-69), 1 for P include: 1) th 5% combined	ass (60-69), le rights; 2) an); 3) the role of
AGM level By Thai Investors Association (TIA) with support from the SEC	treatment are transparent a out of five the criteria cover date (45%), a circulation of s exercised. The and verifiability	e incorporated and sufficiently e CG compon r AGM proced and after the r ufficient information second assess r; and 3) openne	which shareholders' rights l into business operation y disclosed. All form impu- ents to be evaluated anr ures before the meeting meeting (10%). (The first a tion for voting; and 2) facilitat es 1) the ease of attending in ss for Q&A. The third involve es, resolutions and voting re-	s and information is ortant elements of two nually. The assessment (45%), at the meeting issesses 1) advance ting how voting rights can be neetings; 2) transparency is the meeting minutes that			four categories: (80-89), and not		
Thai CAC By Thai Private Sector Collective Action Against Corruption (CAC)	establishmer policies. The (Companies de Declaration of Certification, in managers and	nt of key contro Certification i eciding to becom Intent to kick off ocluding risk asso	Checklist include corrupti ols, and the monitoring a s good for three years. an 18-month deadline to sul essment, in place of policy a ablishment of whistleblowing I stakeholders.)	and developing of tart by submitting a pmit the CAC Checklist for nd control, training of	passed Checkl	ist will move fo se members a	ed by a committe or granting certific re twelve highly i chievements.	ation by the 0	CAC Council
<u>Morningstar</u> Sustainalytics	based on an risk is unmar	assessment on aged. Sources	sk rating provides an ove of how much of a compa s to be reviewed include corp ner media, NGO reports/web	ny's exposure to ESG	more risk is un	managed, the	score is the sum higher ESG risk	is scored.	
		mpany feedbaci Jality & peer revi	k, ESG controversies, issuer iews.	feedback on draft ESG	0-10	Low 10-20	Medium 20-30	High 30-40	Severe 40+
ESG Book	positioned to the principle helps explair over-weightin	outperform of financial manufature risk-action	sustainable companies th ver the long term. The m ateriality including inform djusted performance. Ma th higher materiality and rly basis.	ethodology considers ation that significantly teriality is applied by	The total ESG scores using m	score is calcul ateriality-base	ated as a weight d weights. The s idicating better p	ed sum of the core is scaled	features
MSCI				anagement of financially their exposure to ESG ri					nethodology to
	AAA AA	8.571-10.000	Leader:	leading its industry in m	anaging the most s	ignificant ESG ri	sks and opportunitie	es	
	A BBB BB	5.714-7.142 4.286-5.713 2.857-4.285	Average:	a mixed or unexception industry peers	al track record of m	anaging the mos	t significant ESG ris	sks and opportu	nities relative to
	B CCC	1.429-2.856 0.000-1.428	Laggard:	lagging its industry base	ed on its high expos	ure and failure t	o manage significar	t ESG risks	
Moody's ESG solutions	Moody's ass believes that	esses the deg a company in	ree to which companies	take into account ESG o to its business model an medium to long term.					
Refinitiv ESG rating	based on pu	blicly available	e and auditable data. The	a company's relative ES score ranges from 0 to are 0 to 25 = poor; >25 to 50	100 on relative E	SG performar	nce and insufficie	nt degree of t	
S&P Global				asuring a company's perf ssification. The score ran			of ESG risks, op	portunities, ar	d impacts
	ESG Score	•	Bloomberg score evalu	ating the company's agg	regated Environr	nental, Social			
Bloomberg			score is based on Bloo of Pillar Scores, where	the weights are determin					

Rating regarding the sustainable development of Thai listed companies, both on the SET and MAI, are publicly available on the website of the Securities and Exchange Commission of Thailand (SEC). Currently, ratings available are 1) "CG Score"; 2) "AGM Level"; 3) "Thai CAC"; and 4) THSI. The ratings are updated on an annual basis. FSSIA does not confirm nor certify the accuracy of such ratings. Source: FSSIA's compilation

GENERAL DISCLAIMER

ANALYST(S) CERTIFICATION

Teerapol Udomvej, CFA FSS International Investment Advisory Securities Co., Ltd

The individual(s) identified above certify(ies) that (i) all views expressed in this report accurately reflect the personal view of the analyst(s) with regard to any and all of the subject securities, companies or issuers mentioned in this report; and (ii) no part of the compensation of the analyst(s) was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed herein.

This report has been prepared by FSS International Investment Advisory Securities Company Limited (FSSIA). The information herein has been obtained from sources believed to be reliable and accurate; however FSSIA makes no representation as to the accuracy and completeness of such information. Information and opinions expressed herein are subject to change without notice. FSSIA has no intention to solicit investors to buy or sell any security in this report. In addition, FSSIA does not guarantee returns nor price of the securities described in the report nor accept any liability for any loss or damage of any kind arising out of the use of such information or opinions in this report. Investors should study this report carefully in making investment decisions. All rights are reserved.

This report may not be reproduced, distributed or published by any person in any manner for any purpose without permission of FSSIA. Investment in securities has risks. Investors are advised to consider carefully before making investment decisions.

Company	Ticker	Price	Rating	Valuation & Risks
Bangkok Dusit Medical Services	BDMS TB	THB 28.50	BUY	Downside risks to our DCF-based target price include 1) a slowdown in international patients due to economic concerns, political protests or floods; 2) regulatory risks from drug prices and medical bill controls; and 3) higher-than-expected capex and opex for CoE projects.
Praram 9 Hospital	PR9 TB	THB 19.40	BUY	Downside risks to our DCF-based target price include 1) weak patient volumes following the economic slowdown; 2) regulatory risks from drug price and medical bill controls; and 3) higher-than-expected expenses from its new building.
Bumrungrad Hospital	ВН ТВ	THB 232.00	BUY	Downside risks to our DCF-based target price include 1) a slowdown in international patients due to economic concerns, political protests or floods; 2) regulatory risks from drug prices and medical bill controls; and 3) higher medical fee discount promotions, leading to a weaker EBITDA margin.
Bangkok Chain Hospital	BCH TB	THB 20.60	BUY	Downside risks to our DCF-based target price include 1) a slowdown in international patients due to economic concerns, political protests or floods; 2) regulatory risks from drug prices and medical bill controls; and 3) SSO provision expenses following a limited SSO budget.
Chularat Hospital	CHG TB	THB 2.92	BUY	Downside risks to our DCF-based target price include 1) a slowdown in Thai patient volume due to economic concerns; 2) regulatory risks from drug price and medical bill controls; and 3) SSO provision expenses following limited budgets from the SSO.
Thonburi Healthcare Group	THG TB	THB 41.25	HOLD	Upside risks to our DCF-based target price include 1) a new Covid wave from a new variant; and 2) big-lot sales of Jin Wellbeing County units. Downside risks include 1) regulatory risks from drug prices and medical bill controls; and 2) a slowdown in international patients due to economic concerns.
Ramkhamhaeng Hospital	RAM TB	THB 30.50	BUY	Downside risks to our DCF-based target price include 1) weak patient volumes following the economic slowdown; 2) regulatory risks from drug price and medical bill controls; and 3) losses from its subsidiary companies.

Source: FSSIA estimates

Additional Disclosures

Target price history, stock price charts, valuation and risk details, and equity rating histories applicable to each company rated in this report is available in our most recently published reports. You can contact the analyst named on the front of this note or your representative at Finansia Syrus Securities Public Company Limited.

All share prices are as at market close on 09-Apr-2024 unless otherwise stated.

RECOMMENDATION STRUCTURE

Stock ratings

Stock ratings are based on absolute upside or downside, which we define as (target price* - current price) / current price.

BUY (B). The upside is 10% or more.

HOLD (H). The upside or downside is less than 10%.

REDUCE (R). The downside is 10% or more.

Unless otherwise specified, these recommendations are set with a 12-month horizon. Thus, it is possible that future price volatility may cause a temporary mismatch between upside/downside for a stock based on market price and the formal recommendation.

* In most cases, the target price will equal the analyst's assessment of the current fair value of the stock. However, if the analyst doesn't think the market will reassess the stock over the specified time horizon due to a lack of events or catalysts, then the target price may differ from fair value. In most cases, therefore, our recommendation is an assessment of the mismatch between current market price and our assessment of current fair value.

Industry Recommendations

Overweight. The analyst expects the fundamental conditions of the sector to be positive over the next 12 months. **Neutral.** The analyst expects the fundamental conditions of the sector to be maintained over the next 12 months. **Underweight.** The analyst expects the fundamental conditions of the sector to be negative over the next 12 months.

Country (Strategy) Recommendations

Overweight (O). Over the next 12 months, the analyst expects the market to score positively on two or more of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.

Neutral (N). Over the next 12 months, the analyst expects the market to score positively on one of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.

Underweight (U). Over the next 12 months, the analyst does not expect the market to score positively on any of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.